Roche Presents Spinal Muscular Atrophy Drug Data
On Thursday, Roche (OTC: RHHBY) announced the much-anticipated results from a study of the company's experimental spinal muscular atrophy (SMA) drug, resdiplam. The biotech giant released the full data from its Sunfish trial, which tested patients with type 2 or type 3 SMA between the ages of 2 and 25 to see whether doses of risdiplam would improve their motor function.
The data showed a significant improvement in the motor functions of patients taking risdiplam in comparison to the placebo group. The best performance came from patients between two and five years old -- 78.1% of that group experienced a three-point-plus improvement on their motor function scores in comparison to 52.9% of similarly aged patients taking a placebo.
Image source: Getty Images.
Source Fool.com
